Enagas (0EBQ)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 17.42 |
|---|---|
| 52-week range | 13.02 – 18.18 |
| Return, 1 month / 3 months | +4.9% / +0.6% |
| Return, 1 year / 3 years | +29.0% / +37.7% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 21.4% |
| Worst drawdown (1 year) | -7.5% |
| Average daily value traded | 1.82M EUR |
| Dividend yield | 4.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Enagas is a Spanish energy infrastructure company based in Madrid. It owns and operates the country's gas transmission network, moving natural gas through high-pressure pipelines, and it runs underground storage facilities and regasification terminals that receive liquefied natural gas by ship. Its customers are shippers and gas traders who need to transport or store gas, along with industrial users connected to the system. The company also holds stakes in gas infrastructure projects outside Spain.
The shares are listed on the London Exchange in UK under the code 0EBQ, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Enagas (0EBQ) trades on the London Exchange in UK. It last closed at EUR 17.42 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 306 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.0% and over the last three months it rose 0.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.7% | ||
| From 52-week high | -2.3% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.6% | ||
| 6-month return | 4.2% | ||
| 12-month return, skipping the last month | 23.0% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -7.5% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.82M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 78 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 4.7% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | +4.9% |
| 3 months | +0.6% |
| 6 months | +4.2% |
| 1 year | +29.0% |
| 3 years | +37.7% |
| 5 years | +27.7% |
Signals
| 50-day / 200-day average | 16.71 / 16.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.35 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Jun 2026 | EUR 0.4860 |
| 19 Dec 2025 | EUR 0.3240 |
| 1 Jul 2025 | EUR 0.4860 |
| 10 Dec 2024 | EUR 0.3240 |
| 2 Jul 2024 | EUR 0.8456 |
| 20 Dec 2023 | EUR 0.5638 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.